Form 4: CareDx Director William Hagstrom Exercises Options and Sells 30,000 Shares

CareDx, Inc. Director William A. Hagstrom exercised stock options and subsequently sold 30,000 shares of common stock for approximately $523,413 on May 28, 2025.

Summary

• On May 28, 2025, William A. Hagstrom, a Director of CareDx, Inc. (CDNA), engaged in a series of transactions involving the company's common stock.
• Mr. Hagstrom exercised stock options to acquire a total of 30,000 shares of common stock.
• These options included 4,745 shares at an exercise price of $4.95, 24,745 shares at $7.96, and 510 shares at $5.85.
• Immediately following the exercise, Mr. Hagstrom sold all 30,000 of these newly acquired shares on the open market.
• The shares were sold at a weighted average price of $17.4471 per share, with prices ranging from $17.35 to $17.57.
• The total proceeds from the sale amounted to approximately $523,413.
• Following these transactions, Mr. Hagstrom's direct beneficial ownership of CareDx common stock stands at 53,979 shares.
• Additionally, he retains 4,391 unexercised stock options with an exercise price of $7.96, which vested fully on June 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can sometimes be perceived negatively, this appears to be a routine exercise and sell transaction for personal liquidity and compensation realization, which is a common and expected event for executives.

Positives

• The transactions demonstrate a significant profit for the director, as shares acquired at lower option prices were sold at a substantially higher market price, indicating a successful realization of vested equity.
• The sale of shares by a director can be seen as a normal part of compensation and liquidity management for executives.

Negatives

• A director selling a substantial number of shares (30,000 shares) could be perceived negatively by some investors, potentially signaling a lack of confidence or a desire to diversify holdings.
• The reduction in direct beneficial ownership by 30,000 shares might be viewed as a decrease in the director's direct stake in the company's future performance.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction by a director of CareDx, Inc., a company operating in the healthcare diagnostics industry, specifically in transplant patient care. Such transactions are common for executives managing their equity compensation and personal finances, and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted in various ways; some might view it as a normal liquidity event, while others might see it as a reduction in insider ownership, potentially impacting investor sentiment. However, the director still retains a significant number of shares.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

Keywords

CareDx, CDNA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Beneficial Ownership, Equity Compensation